Impact of active surveillance for prostate cancer on the risk of depression and anxiety

Sci Rep. 2022 Jul 28;12(1):12889. doi: 10.1038/s41598-022-17224-w.

Abstract

Active surveillance (AS) is a standard treatment option for low risk localized prostate cancer. However, the risk of anxiety and depression compared to other curative strategies, namely radical prostatectomy (RP) and radiotherapy (RT), is controversial. This study consisted in a French representative sample of 4174 5-years cancer survivors. Self-reported data, including quality-of-life assessment, were prospectively collected through telephone interviews. Among the 447 survivors with PC, we selected 292 patients with localized prostate cancer, T1-T2 stage, Gleason score ≤ 7 and we compared anxiety and depressive symptoms according to treatment strategy. Among patients on AS, 14.9% received curative treatment during the 5 years of follow-up. Anxiety was reported in 34.3% of cases in the AS group versus 28.6% in the RP group and 31.6% in the RT group (p = 0.400), while depressive symptoms were reported in 14.9% of cases in the AS group versus 10.7% in the RP group and 22.8% in the RT group (p = 0.770). Consumption of anxiolytics reported did not vary significantly between the 3 groups (p = 0.330). In conclusion, patients managed with AS for localized prostate cancer do not report more anxiety or depressive symptoms than patients managed with curative treatment, encouraging the extended use of active surveillance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anxiety* / epidemiology
  • Anxiety* / etiology
  • Depression* / epidemiology
  • Depression* / etiology
  • Humans
  • Male
  • Prostatectomy / adverse effects
  • Prostatic Neoplasms* / radiotherapy
  • Prostatic Neoplasms* / therapy
  • Watchful Waiting*